VivoSeq
Other

Excessive Daytime Sleepiness

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Excessive Daytime Sleepiness is an early-stage landscape with 0 programs across 1 company. The most active players are Jazz Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed8 · 67%
Withdrawn2 · 17%
Terminated2 · 17%

Clinical Trials

Trial Activity

12 trials

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness
Completed·AAbbott·Phase 1·NCT01124851·36 enrolled
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Completed·BBioprojet·Phase 3·NCT01066442·273 enrolled
Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease
Completed·SSecond Affiliated Hospital of Soochow University·Phase 4·NCT04870372·141 enrolled
Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)
Completed·—·Phase 2·NCT00641186·30 enrolled
Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients
Completed·BBioprojet·Phase 2·NCT00642928·108 enrolled
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Completed·TTheranexus·Phase 2·NCT03624920·77 enrolled
A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 2·NCT01485770·33 enrolled
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Completed·BBioprojet·Phase 3·NCT01036139·268 enrolled
Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy
Terminated·UUniversity of South Florida·Phase 2·NCT01348607·1 enrolled
Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease
Terminated·AAmsterdam UMC, location VUmc·Phase 4·NCT02473562·22 enrolled
Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease
Withdrawn·US Department of Veterans Affairs·N/A·NCT00393562
Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
Withdrawn·BBioprojet·Phase 3·NCT02978651

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)